CeriBell, Inc. (NASDAQ:CBLL – Get Free Report) CEO Xingjuan Chao sold 39,000 shares of the firm’s stock in a transaction that occurred on Monday, June 8th. The shares were sold at an average price of $18.33, for a total value of $714,870.00. Following the completion of the transaction, the chief executive officer owned 816,317 shares of the company’s stock, valued at approximately $14,963,090.61. This represents a 4.56% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Xingjuan Chao also recently made the following trade(s):
- On Thursday, May 21st, Xingjuan Chao sold 6,030 shares of CeriBell stock. The stock was sold at an average price of $18.00, for a total transaction of $108,540.00.
- On Tuesday, May 5th, Xingjuan Chao sold 39,000 shares of CeriBell stock. The stock was sold at an average price of $20.10, for a total transaction of $783,900.00.
- On Monday, April 6th, Xingjuan Chao sold 39,000 shares of CeriBell stock. The stock was sold at an average price of $18.40, for a total transaction of $717,600.00.
CeriBell Stock Performance
NASDAQ CBLL traded up $0.05 on Wednesday, hitting $18.55. 119,291 shares of the stock were exchanged, compared to its average volume of 316,275. The company has a debt-to-equity ratio of 0.14, a current ratio of 10.44 and a quick ratio of 10.01. The business’s fifty day moving average is $18.97 and its 200 day moving average is $19.63. CeriBell, Inc. has a 52 week low of $10.85 and a 52 week high of $24.33. The company has a market capitalization of $703.82 million, a PE ratio of -11.36 and a beta of 0.84.
Institutional Trading of CeriBell
Several institutional investors have recently added to or reduced their stakes in the company. Russell Investments Group Ltd. increased its position in CeriBell by 41.4% during the fourth quarter. Russell Investments Group Ltd. now owns 2,918 shares of the company’s stock worth $64,000 after acquiring an additional 854 shares during the period. Sei Investments Co. increased its position in CeriBell by 2.3% during the first quarter. Sei Investments Co. now owns 50,360 shares of the company’s stock worth $923,000 after acquiring an additional 1,125 shares during the period. Caitong International Asset Management Co. Ltd increased its position in CeriBell by 3,971.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock worth $28,000 after acquiring an additional 1,231 shares during the period. Deutsche Bank AG increased its position in CeriBell by 1.7% during the fourth quarter. Deutsche Bank AG now owns 85,182 shares of the company’s stock worth $1,868,000 after acquiring an additional 1,393 shares during the period. Finally, Strs Ohio bought a new position in CeriBell during the first quarter worth about $27,000.
Analyst Ratings Changes
CBLL has been the topic of several research analyst reports. Canaccord Genuity Group dropped their price objective on shares of CeriBell from $28.00 to $25.00 and set a “buy” rating on the stock in a research report on Tuesday, May 12th. Weiss Ratings raised shares of CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, May 27th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $22.20.
Read Our Latest Stock Report on CeriBell
About CeriBell
CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.
The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.
Featured Articles
- Five stocks we like better than CeriBell
- Chewy’s Growth Engine Is Stronger Than the Market Thinks
- Nebius Group’s £1.7 Billion UK Expansion Fuels Bullish Case Despite the Pullback
- An Analyst Just Raised Tesla’s Price Target by 227%—Here’s Why
- AST SpaceMobile’s SpaceX Catalyst Could Come With a Volatility Warning
Receive News & Ratings for CeriBell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CeriBell and related companies with MarketBeat.com's FREE daily email newsletter.
